Wyeth has exercised its right to license three bone anabolic drug targets from a 2003 osteoporosis research agreement with Galapagos, resulting in a $1.4 million milestone payment to Galapagos. This is the second milestone reached in the osteoporosis collaboration. Galapagos has applied its osteoporosis disease expertise to discover and validate novel drug targets for Wyeth. In November 2004, Wyeth selected a set of these targets for internal validation. Under the terms of the 2003 ag...